Clinical Trial

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2030-05 -> 2030-11 2026-08-01
minor Completion pushed: 2037-05 -> 2037-11 2026-08-01
Trial Details
NCT Number NCT07206849
Lead Sponsor Nationwide Children's Hospital
Collaborators: Day One Biopharmaceuticals, Inc.
Conditions High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Metastatic Brain Tumor
Enrollment 79 participants
Start Date 2026-11
Primary Completion 2030-11 (estimated)
Study Completion 2037-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-31